BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mio USD) | Schätzung (Mio USD) | Abweichung |
|---|